8-K: Bluejay Diagnostics' Sepsis Test Abstract Accepted for SAEM

Bluejay Diagnostics announced its Symphony IL-6 Test abstract was accepted for presentation at the 2026 Society of Academic Emergency Medicine Annual Meeting, detailing new clinical data from the SYMON-I study.

Summary

• Bluejay Diagnostics' abstract related to its Symphony IL-6 Test has been accepted for presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting.
• The presentation will report findings from SYMON-I, a multicenter pilot clinical study evaluating interleukin-6 (IL-6) levels in sepsis patients admitted or intended for the intensive care unit (ICU).
• The analysis evaluates the relationship between IL-6 levels measured in the emergency department and organ dysfunction, as assessed by Sequential Organ Failure Assessment (SOFA) scores, during the first three days of hospitalization.
• The SAEM Annual Meeting is scheduled for May 18-21, 2026, in Atlanta, Georgia.
• The Symphony IL-6 Test is Bluejay's lead product candidate, designed to determine patient acuity for sepsis triage and monitoring.
• The Symphony IL-6 Test is currently an investigational device, limited by United States law to investigational use, and lacks regulatory clearance from the U.S. Food and Drug Administration (FDA).
• The SYMON Clinical Study Program includes SYMON-I (pilot study), SYMON-II (pivotal study for 510(k) application to the FDA), and SYMON-III (pilot study for infection severity and sepsis risk).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the acceptance of clinical data for presentation at a reputable conference validates the company's research and moves its lead product candidate forward in public awareness and scientific discourse, despite the product still being investigational.

Positives

• The abstract's acceptance for presentation at the prestigious 2026 Society of Academic Emergency Medicine Annual Meeting validates Bluejay's research and clinical development efforts.
• Findings from the SYMON-I study suggest that IL-6 measured in the emergency department may be associated with subsequent organ dysfunction in patients with sepsis and septic shock.
• These data contribute to the growing body of evidence evaluating IL-6 as a potential biomarker for the early assessment of critically ill patients.
• The Symphony IL-6 Test is designed to provide accurate, reliable results in approximately 20 minutes, which could aid medical professionals in making earlier and better triage and treatment decisions for sepsis.
• The ongoing SYMON-II validation study is intended to further evaluate IL-6 as a prognostic biomarker associated with mortality and other clinically meaningful outcomes, moving closer to regulatory submission.

Negatives

• The Symphony IL-6 Test is currently an investigational device and is limited by U.S. law to investigational use.
• Bluejay Diagnostics does not yet have regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Symphony System, meaning it cannot be marketed as a diagnostic product in the United States.
• Actual results or events could differ materially from forward-looking statements due to known and unknown risks, uncertainties, and other factors, as highlighted in the company's risk disclosures.

Risks

• The Symphony IL-6 Test is an investigational device and is limited by United States law to investigational use.
• Bluejay Diagnostics does not yet have regulatory clearance for the Symphony System and will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States.
• Forward-looking statements are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by these statements, including those discussed under Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Future Outlook

The SYMON-II validation study is ongoing and intended to further evaluate IL-6 as a prognostic biomarker associated with mortality and other clinically meaningful outcomes in critically ill patients. Bluejay Diagnostics plans to use the results from the SYMON-II study to support a 510(k) application to the FDA for regulatory clearance of the Symphony IL-6 Test.

Management Comments

• Nathan Shapiro, M.D., Vice Chairman of Emergency Medicine Research at Beth Israel Deaconess Medical Center and Professor of Emergency Medicine at Harvard Medical School and the clinical trial national principal investigator, stated: "The findings from the SYMON-I study suggest that IL-6 measured in the emergency department may be associated with subsequent organ dysfunction in patients with sepsis and septic shock. These data contribute to the growing body of evidence evaluating IL-6 as a potential biomarker in the early assessment of critically ill patients."
• Mark Feinberg, M.D., Chief Medical Advisor at Bluejay Diagnostics and Professor of Medicine at Harvard Medical School, commented: "The SAEM Annual Meeting provides an opportunity to present emerging clinical data evaluating IL-6 as a biomarker associated with the inflammatory response and organ dysfunction in sepsis. Bluejay’s ongoing SYMON-II validation study is intended to further evaluate IL-6 as a prognostic biomarker associated with mortality and other clinically meaningful outcomes in critically ill patients."

Industry Context

StockSavvy.ai notes that the acceptance of an abstract for presentation at a major academic emergency medicine conference like SAEM is a significant step for a medical diagnostics company, particularly one developing a rapid near-patient test for critical conditions like sepsis. Sepsis diagnosis and management remain a major challenge in emergency medicine, and the identification of reliable early biomarkers like IL-6 could significantly improve patient outcomes by enabling faster triage and treatment decisions. This development positions Bluejay Diagnostics as a potential innovator in this critical area, aligning with broader industry trends towards rapid, point-of-care diagnostics.

Stakeholder Impact

• Shareholders: Positive impact due to validation of research and progress towards regulatory approval, potentially increasing company visibility and investor confidence.
• Medical Professionals/Customers: Potential for a new, rapid diagnostic tool to improve sepsis triage and monitoring, leading to better patient outcomes.
• Patients: Potential for earlier and more effective treatment of sepsis, reducing organ dysfunction and mortality.

Next Steps

• Presentation of SYMON-I study findings at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting from May 18-21, 2026, in Atlanta, Georgia.
• Continuation of the SYMON-II validation study to further evaluate IL-6 as a prognostic biomarker associated with mortality and other clinically meaningful outcomes.
• Preparation for a 510(k) application to the FDA using results from the SYMON-II study for regulatory clearance of the Symphony IL-6 Test.

Key Dates

Recommendation

The acceptance of the abstract for presentation at a key industry conference is a positive validation of Bluejay Diagnostics' research and clinical development efforts for its lead product candidate, the Symphony IL-6 Test. This enhances visibility and scientific credibility. However, the product remains investigational and requires significant further validation through the SYMON-II study and subsequent FDA regulatory clearance before commercialization. Given the early stage of market readiness, a "hold" recommendation is appropriate for investors to monitor the progress of the SYMON-II study and the FDA application process, as these will be critical determinants of future value.

Keywords

Sepsis, IL-6 Test, Symphony System, Diagnostics, Biomarker, Emergency Medicine, SAEM, Clinical Study, FDA, Medical Device, Bluejay Diagnostics